Ferrer withdraws Egrifta marketing authorisation application in Europe
Ferrer formally notified the European Medicines Agency of its decision. The company submitted the MAA for Egrifta to the agency on 31 May 2011, during which it was
US-based gene therapy biotech Seawolf Therapeutics and Sanofi have signed a multi-target research partnership and exclusive licensing deal worth up to $1.2bn to develop treatments for bleeding disorders and other undisclosed indications.
EPS is offering analytical services, such as nuclear magnetic resonance spectroscopy (NMR) and liquid chromatography-mass spectrometry (LC-MS), and microbiological testing such as comprehensive drug resistance profiling and biofilm